• Linda Avey

    Co-founder & CEO at Precise.ly, Inc.

    Linda Avey is best known as the co-founder of the world’s first personal genetics service 23andMe. In 2006 she co-founded the company with Anne Wojcicki and Paul Cusenza.  By 2008 the company’s method of using saliva and working directly with consumers earned them the award of Time Magazine’s Invention of the Year. In 2009, Avey left 23andMe and has started a variety of efforts over the years in pursuit of her main interest in the acceleration of personalized medicine, using genetic profiles to target the right drug to the right person at the correct dose.

    Avey is now the Co-founder & CEO at Precise.ly, Inc. that is working to expand genetic testing into India and the developing world. She has more than 25 years experience in the biopharmaceutical industry in San Francisco, Boston, San Diego, and Washington, D.C. Prior to starting 23andMe, she developed translational research collaborations with academic and pharmaceutical partners for Affymetrix and Perlegen Sciences. She also spent time at Applied Biosystems during the early days of the human genome project. The advent of high density genome-wide scanning technologies brought huge potential for significant discoveries. However, the lack of sufficient funding to enable adequate studies prompted Linda to think of a new research model. These ideas led to the formation of 23andMe.

     

Related Video Conversations

  • Scheduled: June 27, 2019 5:30 PM PST

    The Co-Founder of 23andMe on the Next Phase of Consumer Genetic Testing

    Few people have as much perspective on what average people can know about their genetic makeup both now and in the near future than Linda Avey, the co-founder of the pioneering biotech company 23andMe. That company offered the world’s first personal genetics service and its method of using saliva and working directly with consumers earned the award of Time Magazine’s Invention of the Year in 2008. It also set off a wave of competition and growth in the field throughout the developing world. Ten years later Avey has co-founded a new company that is positioned for the next phase of expanding easy access to genetic testing in the developing world, particularly in India. And this month Avey will share her thoughts on the state of genetic testing in developed and developing world alike as our next featured guest at What’s Now: San Francisco.

    Participants: Linda Avey